Sales Growth YoY (Last Twelve Months): Corcept Therapeutics Corp (CORT)

Corcept Therapeutics (CORT) dominates the cortisol receptor modulation segment, possessing absolute pricing power. Sales volume growth compared to the same period last year over the past 12 months confirms this status, and 30.40 reflects the latest value of the metric. However, reliance on a single drug and the risk of generics create vulnerability. Stable demand for endocrine therapy currently provides the company with a reliable cash flow.
Corcept Therapeutics Inc. (CORT) - metric breakdowns and financial figures

Corcept Therapeutics (CORT) specializes in biopharmaceuticals, implementing "green chemistry" principles to optimize resources during drug synthesis. This indicator reflects revenue dynamics over the last twelve months relative to the same period last year. It is critical for investors to assess the sustainability of this growth as confirmation of market demand for the drugs. Analyzing the company's TTM annual revenue growth rate helps identify risks of asset overheating or capital stagnation.